000156718 001__ 156718
000156718 005__ 20240229123113.0
000156718 0247_ $$2doi$$a10.1111/bpa.12866
000156718 0247_ $$2pmid$$apmid:32502305
000156718 0247_ $$2ISSN$$a1015-6305
000156718 0247_ $$2ISSN$$a1750-3639
000156718 0247_ $$2altmetric$$aaltmetric:83472890
000156718 037__ $$aDKFZ-2020-01056
000156718 041__ $$aeng
000156718 082__ $$a610
000156718 1001_ $$00000-0003-1239-7757$$aEllison, David W$$b0
000156718 245__ $$acIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.
000156718 260__ $$aOxford$$bWiley-Blackwell$$c2020
000156718 3367_ $$2DRIVER$$aarticle
000156718 3367_ $$2DataCite$$aOutput Types/Journal article
000156718 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601531856_4384$$xReview Article
000156718 3367_ $$2BibTeX$$aARTICLE
000156718 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156718 3367_ $$00$$2EndNote$$aJournal Article
000156718 500__ $$a2020 Sep;30(5):863-866
000156718 520__ $$aAdvances in our understanding of the biological basis and molecular characteristics of ependymal tumors since the latest iteration of the World Health Organization (WHO) classification of CNS tumors (2016) have prompted the cIMPACT-NOW group to recommend a new classification. Separation of ependymal tumors by anatomic site is an important principle of the new classification and was prompted by methylome profiling data to indicate that molecular groups of ependymal tumors in the posterior fossa and supratentorial and spinal compartments are distinct. Common recurrent genetic or epigenetic alterations found in tumors belonging to the main molecular groups have been used to define tumor types at intracranial sites; C11orf95 and YAP1 fusion genes for supratentorial tumors and two types of posterior fossa ependymoma defined by methylation group, PFA and PFB. A recently described type of aggressive spinal ependymoma with MYCN amplification has also been included. Myxopapillary ependymoma and subependymoma have been retained as histopathologically defined tumor types, but the classification has dropped the distinction between classic and anaplastic ependymoma. While the cIMPACT-NOW group considered that data to inform assignment of grade to molecularly defined ependymomas are insufficiently mature, it recommends assigning WHO grade 2 to myxopapillary ependymoma and allows grade 2 or grade 3 to be assigned to ependymomas not defined by molecular status.
000156718 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000156718 588__ $$aDataset connected to CrossRef, PubMed,
000156718 7001_ $$aAldape, Kenneth D$$b1
000156718 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b2$$udkfz
000156718 7001_ $$aFouladi, Maryam$$b3
000156718 7001_ $$aGilbert, Mark R$$b4
000156718 7001_ $$aGilbertson, Richard J$$b5
000156718 7001_ $$aHawkins, Cynthia$$b6
000156718 7001_ $$aMerchant, Thomas$$b7
000156718 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b8$$udkfz
000156718 7001_ $$00000-0003-3583-8308$$aVenneti, Sriram$$b9
000156718 7001_ $$00000-0002-9423-4099$$aLouis, David N$$b10
000156718 773__ $$0PERI:(DE-600)2029927-8$$a10.1111/bpa.12866$$gp. bpa.12866$$n5$$p863-866$$tBrain pathology$$v30$$x1750-3639$$y2020
000156718 909CO $$ooai:inrepo02.dkfz.de:156718$$pVDB
000156718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000156718 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000156718 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000156718 9141_ $$y2020
000156718 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-02-26$$wger
000156718 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN PATHOL : 2018$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-02-26
000156718 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN PATHOL : 2018$$d2020-02-26
000156718 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000156718 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000156718 980__ $$ajournal
000156718 980__ $$aVDB
000156718 980__ $$aI:(DE-He78)HD01-20160331
000156718 980__ $$aI:(DE-He78)B062-20160331
000156718 980__ $$aUNRESTRICTED